(4S)-3-[(tert-butoxy)carbonyl]-1,3-thiazolidine-4-carboxylic acid, 99.0%, 25g

2,6-BIS((S)-4-((S)-SEC-BUTYL)-4,5-DIHYDROOXAZOL-2-YL)PYRIDINE, 95%, 250mg

H-Gly-OtBu.HCl, 98.00%, 25g

3-G1 2AB (500pmol/vial)1vial

4-[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine, 95.0%, 1g

DECURSINOL, 95%, 5mg

(3,3-Dimethoxycyclobutane-1,1-diyl)dimethanol, 95.0%, 250mg

Pyren-1-amine, 95.0%, 10g

Plan stress-free PLPOLi 5x/0.12 IOS objective for iScope incident polarization, no cover glass correction. Working distance 15.5 mm

(R)-5,5'-BIS(DIPHENYLPHOSPHINO)-4,4'-BIBENZO[D][1,3]DIOXOLE, 95%, 100mg

(S)-2-(((S)-1-Ethoxy-1-oxopentan-2-yl)amino)propanoic acid, 95.0%, 200g

TERT-BUTYL METHYL(3-METHYLAZETIDIN-3-YL)CARBAMATE, 95.0%, 500mg

3-(Dimethylamino)-1-(naphthalen-1-yl)propan-1-one hydrochloride, 95.0%, 25g